MAMark T. Albrecht

Mark T. Albrecht

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mark T. Albrecht has a total of 13 co-authors. Here are the top co-authors by number of shared publications:

  • Anna C. Jacobs

    Biomedical Advanced Research and Development Authority, Department of Health and Human Services, Washington, DC 20024, USA

    1 shared publication
  • Edwin O. Nuzum

    Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA

    1 shared publication
  • George Risi

    Biomedical Advanced Research and Development Authority, Department of Health and Human Services, Washington, DC 20024, USA

    1 shared publication
  • George W. Christopher

    Joint Program Management Office, Medical Countermeasure Systems, 1564 Freedman Drive, Fort Detrick, MD 21702, USA

    1 shared publication
  • Helen F. Schiltz

    Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Bethesda, MD 20892-9826, USA

    1 shared publication
  • Lucy A. Ward

    Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA

    1 shared publication

Latest Publications

  • Open Access

    Impact of Bacterial Infections and Antibiotic Use on Hospitalized COVID-19 Patients: An Emerging Infections Network Survey

    by Anna C. Jacobs, Lynn Khosrowshahi, George Risi, Susan Beekmann, Philip M. Polgreen, the COVID-19 Study Team, Mark Albrecht

    The SARS-CoV-2 pandemic has had a significant impact on the United States healthcare system. This is exacerbated by antimicrobial-resistant bacterial pathogens endemic to healthcare settings. Respiratory viral infections are known to predispose patients to bacterial infections, which were a major contributor to mortality in previous pandemics. This study’s goal was to gain an understanding of bacterial infections in hospitalized COVID-19 patients. A case form for COVID-19 patients with bacterial infections was developed and sent to clinicians on the Emerging Infections Network listserv. The case form included 22 questions on patient demographics, COVID-19 and bacterial infection and treatment, and patient outcome. One hundred and nine patient cases were collected and analyzed. The majority of patients (59.6%) were critically ill, and 66.9% of patients were diagnosed with sepsis. Empiric and directed antibiotics were administered to 81.6% and 94.5% of patients, respectively. Thirty-one infections were not resolved with antibiotics, and of those patients, 74.2% died. Unresolved bacterial infections were found to be a significant contributor to mortality in this case series. These bacterial infections can most likely be attributed to long hospital stays and exposure to nosocomial pathogens. Thus, unresolved nosocomial bacterial infections warrant additional attention during future events where there is a strain on the US healthcare system.

  • Open Access

    Challenges, Progress, and Opportunities: Proceedings of the Filovirus Medical Countermeasures Workshop

    by Rona Hirschberg, Lucy A. Ward, Nicole Kilgore, Rebecca Kurnat, Helen Schiltz, Mark T. Albrecht, George W. Christopher, Ed Nuzum

    On August 22–23, 2013, agencies within the United States Department of Defense (DoD) and the Department of Health and Human Services (HHS) sponsored the Filovirus Medical Countermeasures (MCMs) Workshop as an extension of the activities of the Filovirus Animal Non-clinical Group (FANG). The FANG is a federally-recognized multi-Agency group established in 2011 to coordinate and facilitate U.S. government (USG) efforts to develop filovirus MCMs. The workshop brought together government, academic and industry experts to consider the needs for filovirus MCMs and evaluate the status of the product development pipeline. This report summarizes speaker presentations and highlights progress and challenges remaining in the field.